3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
3
Urologic Diseases
2
Urinary Bladder Diseases
2
Carcinoma, Transitional Cell
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Mitomycin
3
vofatamab
2
pembrolizumab
2
Standard of Care
2
Cystectomy
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
trifluridine tipiracil drug combination
1
testosterone 17 beta-cypionate
1
palbociclib
1
enfortumab vedotin
1
atezolizumab
1
Water
1
Valsartan
1
Urinary Diversion
1
Tranexamic Acid
1
Therapeutics
1
Testosterone Propionate
1
Sunitinib
1
Stents
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Practice Guidelines as Topic
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
Methyltestosterone
1
Immune Checkpoint Inhibitors
1
Ice
1
Hydroxychloroquine
1
Health Information Exchange
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Urologic Diseases
×
vofatamab
×
Genitourinary
×
Clear all
NCT03123055
2020-03-18
FIERCE-22
Rainier Therapeutics
Phase 1/2
Terminated
28 enrolled
8 charts
NCT02401542
2020-03-09
FIERCE-21
Rainier Therapeutics
Phase 1/2
Terminated
71 enrolled
9 charts